Am I right in thinking that the FDA will not require CXS to...

Am I right in thinking that the FDA will not require CXS to retest again? Will CXS present the FDA with the updated data (released last December with bigger sample size) showing a much better cytogenetic response in chronic phase patients with the mutation? Or will the FDA still vote on the original data submitted? ie. will an entirely new NDA be required?